{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:32:36Z","timestamp":1785907956363,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjmed.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T10:43:18Z","timestamp":1642848198000},"page":"S44-S48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S1","title":["Developing Therapy for Transthyretin Amyloidosis"],"prefix":"10.1016","volume":"135","author":[{"given":"Courtney M.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.amjmed.2022.01.002_bib0001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.amjmed.2022.01.002_bib0002","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.002_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.002_bib0004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.002_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2022.01.002_bib0006","first-page":"A19616","article-title":"Abstract 19616: AG10 stabilizes pathogenic TTR variants with high potency \u2013 potential for an effective treatment for TTR cardiomyopathy","volume":"136","author":"Graef","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2022.01.002_bib0007","unstructured":"Alnylam Pharmaceuticals, Inc. Alnylam reports positive topline results from HELIOS-A phase 3 study of vutrisiran in patients with hATTR amyloidosis with polyneuropathy. January 7, 2021. Available at:https:\/\/www.businesswire.com\/news\/home\/20210107005224\/en\/Alnylam-Reports-Positive-Topline-Results-from-HELIOS-A-Phase-3-Study-of-Vutrisiran-in-Patients-with-hATTR-Amyloidosis-with-Polyneuropathy. Accessed February 8, 2022."},{"key":"10.1016\/j.amjmed.2022.01.002_bib0008","unstructured":"Ionis Pharmaceuticals, Inc. Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen. July 29, 2021. Available at:https:\/\/www.prnewswire.com\/news-releases\/ionis-completes-enrollment-in-pivotal-neuro-ttransform-study-of-eplontersen-301343941.html. Accessed February 8, 2022."},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.002_bib0009","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2022.01.002_bib0010","unstructured":"Prothena Corporation plc. Prothena reports positive 9 month results from phase 1 long-term extension study of PRX004, the first investigational anti-amyloid immunotherapy for the treatment of ATTR amyloidosis. December 9, 2020. Available at:https:\/\/ir.prothena.com\/press-releases\/news-release-details\/2020\/Prothena-Reports-Positive-9-Month-Results-from-Phase-1-Long-term-Extension-Study-of-PRX004-the-First-Investigational-Anti-Amyloid-Immunotherapy-for-the-Treatment-of-ATTR-Amyloidosis\/. Accessed February 8, 2022."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:26:07Z","timestamp":1757582767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"alternative-id":["S0002934322000237"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.002","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing Therapy for Transthyretin Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}